明德生物(002932) - 2025 Q2 - 季度业绩预告

I. Current Period Performance Forecast The company expects net profit attributable to shareholders for H1 2025 to significantly decrease by 76.98% to 84.65%, with a profit range of 10 million to 15 million yuan, while net loss after non-recurring items is projected to widen Key Financial Data for H1 2025 Performance Forecast | Item | Current Reporting Period (H1 2025) | Prior Period (H1 2024) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (yuan) | Profit: 10,000,000 - 15,000,000 | Profit: 65,162,600 | | Year-on-Year Change | Decrease: 76.98% - 84.65% | - | | Net Profit After Non-Recurring Items (yuan) | Loss: 35,000,000 - 45,000,000 | Loss: 28,822,700 | | Basic Earnings Per Share (yuan/share) | 0.05 - 0.07 | 0.28 | II. Communication with Accounting Firms The performance forecast data has not been pre-audited by a certified public accountant and represents preliminary estimates by the company's finance department - This performance forecast has not been pre-audited by a certified public accountant[3] III. Explanation of Performance Changes The significant year-on-year decrease in H1 2025 net profit is primarily due to a substantial reduction in non-recurring income, specifically government subsidies of 70.2953 million yuan received in the prior period - The year-on-year decline in net profit is primarily influenced by non-recurring gains and losses, with a significant reduction in government subsidies and other income during the current reporting period[4] - In the prior period, other income recognized as non-recurring gains and losses amounted to 70.2953 million yuan, primarily from government subsidies[4] IV. Risk Warning and Other Related Disclosures The company advises investors that this performance forecast is a preliminary, unaudited estimate, and final financial data will be based on the officially disclosed H1 2025 semi-annual report, urging caution regarding investment risks - This performance forecast represents preliminary estimates by the company's finance department and has not been audited by an auditing firm[5] - Specific H1 2025 financial data will be detailed in the company's officially disclosed semi-annual report, and investors are reminded to be aware of investment risks[5]